(“SPH”) of the Company's 50 per cent. holding in Biotec Holding GmbH (“Biotec”) (together with the outstanding shareholder loan of EUR 6,227,092.02 made by the Company to Biotec and its subsidiaries (the “Shareholder Loan”) for £5.2m in cash (the “Sale”).
Highlights
- Sale of 50% stake in Biotec, the Group's manufacturing joint venture with Sphere
- Biome will receive a cash consideration of £5.2m
- The sale will allow the Group to focus on its strategy to develop high margin, application led products.
John Standen, Chairman said:
“This disposal is an important step for the Company and it will allow our Bioplastics Division to work exclusively on developing and commercialising wholly owned intellectual property. The Board believes it is an appropriate time to divest its stake given the weak and uncertain market segments serviced by Biotec. In addition, we believe Biotec's dedicated operations will become increasingly less relevant to Biome's operations in the coming years as we focus on delivering our strategy to develop products with higher levels of functionality which are likely to require different production technologies.”
Highlights
- Sale of 50% stake in Biotec, the Group's manufacturing joint venture with Sphere
- Biome will receive a cash consideration of £5.2m
- The sale will allow the Group to focus on its strategy to develop high margin, application led products.
John Standen, Chairman said:
“This disposal is an important step for the Company and it will allow our Bioplastics Division to work exclusively on developing and commercialising wholly owned intellectual property. The Board believes it is an appropriate time to divest its stake given the weak and uncertain market segments serviced by Biotec. In addition, we believe Biotec's dedicated operations will become increasingly less relevant to Biome's operations in the coming years as we focus on delivering our strategy to develop products with higher levels of functionality which are likely to require different production technologies.”
Companies in this article
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)
